













ARTICLE OPEN



Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors

Iris H. Nelen ^{1,2,12}, Soetkin Leys ^{1,2,12}, Sarah-Lee Bekaert ^{1,2}, Fanny De Vloed^{1,2}, Fien Martens^{1,2}, Ellen Sanders^{1,2}, Angeline Praveena Enton Raj^{3,4,5}, Annika Jeschke^{3,4,5}, Shunya Ohmura ^{3,4,5}, Thomas G. P. Grünewald ^{3,4,5,6}, Liselot M. Mus ^{2,7,8}, Tim Lammens ^{2,7,9}, Nadine Van Roy ^{1,2}, Bram De Wilde^{1,2,9}, Frank Speleman ^{1,2}, Annelies Van Hemelryk ^{1,2,10,11}, Lisa Depestel ^{1,2} and Kaat Durinck ^{1,2}✉

© The Author(s) 2026

Tumor cells often cope with elevated levels of replication stress (RS) causing increased dependency on ATR-CHK1 signaling. We previously presented RRM2, the regulatory component of the ribonucleotide reductase (RNR) enzyme, as novel dependency in neuroblastoma (NB), in keeping with its role in RS resistance. We identified strong synergism for combined RRM2-CHK1 inhibition using the iron chelator triapine and prexasertib respectively. To obtain direct RNR targeting, we evaluated a novel inhibitor, TAS1553, specifically disrupting the RNR complex in this study. Treatment with TAS1553 impedes cell growth and induces enhanced RS, DNA damage and apoptosis. We demonstrated strong synergism between TAS1553 and the CHK1 inhibitors prexasertib and SRA737 in both NB cell lines and tumoroids as well as in sarcoma cell lines. We confirm drug synergism in vivo in a NB zebrafish xenograft model, further underscoring the broad clinical potential of combinatorial RRM2-CHK1 inhibition. Altogether, this study paves the way for further preclinical testing of second generation RRM2 and CHK1 inhibitors such as TAS1553 and SRA737 in neuroblastoma and sarcomas.

Cell Death and Disease (2026)17:263; <https://doi.org/10.1038/s41419-026-08514-6>

INTRODUCTION

Cancer cells often display high proliferation rates causing increased levels of replication stress (RS), defined as slowing, stalling or the collapse of replication forks, resulting in increased DNA damage [1]. Neuroblastoma (NB), a deadly pediatric tumor of the sympathetic nervous system, displays high basal levels of RS [2] and adopts a RS resistance phenotype, which renders them particularly sensitive to pharmacological inhibition of the ATR-CHK1 RS induced signaling pathway [3]. Indeed, previous studies indicate that NB is one of the most sensitive tumors to CHK1 inhibition [2, 4]. Moreover, studies in ALK-driven genetically engineered mouse models of NB showed complete tumor regression upon ATR inhibition, highlighting the effectiveness of therapeutically targeting the DNA damage response (DDR) pathway in NB [5, 6].

Cancer cells exhibiting enhanced RS are particularly vulnerable to dNTP depletion during early S-phase and therefore require continuous and sufficiently high levels of dNTP pool supplementation. In line with this observation, we previously identified

ribonucleotide reductase subunit M2 (RRM2) as a novel therapeutic target, which is synergistic with pharmacological CHK1 inhibition in high-risk NB [7]. RRM2 is part of the ribonucleotide reductase (RNR) enzyme, where it forms a heterotetrameric dimer together with RRM1, which catalyses the rate-limiting step in de novo dNTP synthesis [8]. In contrast to RRM1, RRM2 expression is tightly regulated during cell cycle progression with elevated levels during the S-phase [9, 10]. The functional importance of RRM2 is more broadly marked by its overexpression in several adult cancers, including lung cancer [11, 12], prostate cancer [13] and melanoma [14, 15]. More recent work has also converged towards its critical role in the context of pediatric entities including Ewing sarcoma (EWS) [16, 17], retinoblastoma [18], atypical teratoid rhabdoid tumors [19, 20] and hepatoblastoma [21].

Given the broad role of RRM2 across multiple tumor types, several RRM2 inhibitors have been developed, such as hydroxyurea (HU) and triapine (3-AP). HU penetrates the RNR complex and destroys the tyrosyl free radical via one electron oxidation [22, 23]. Consequently, the nucleoside diphosphate (NDP)

¹Pediatric Precision Oncology Lab (PPOL), Department of Biomolecular Medicine, Ghent University, Ghent, Belgium. ²Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

³Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. ⁴Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany. ⁵National Center for Tumor Diseases (NCT), NCT Heidelberg, Heidelberg, Germany. ⁶Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany. ⁷Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.

⁸Department of Diagnostic Sciences, Ghent University, Ghent, Belgium. ⁹Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium. ¹⁰Laboratory of Myeloid Cell Biology in Tissue Damage and Inflammation, VIB-UGhent Center for Inflammation Research, Ghent, Belgium. ¹¹Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium. ¹²These authors contributed equally: Iris H. Nelen, Soetkin Leys. ✉email: kaat.durinck@ugent.be

Edited by: Professor Paul Ekert

Received: 13 May 2025 Revised: 19 January 2026 Accepted: 16 February 2026

Published online: 25 February 2026

reduction reaction is inhibited. 3-AP is an iron chelator, interacting with the iron molecule used by RRM2. This interaction results in the production of reactive oxygen species that inactivate the RNR complex via quenching of the tyrosyl free radical [24]. Both compounds have been tested extensively in cancer patients but were shown to be associated with rapid resistance and significant toxicity [25, 26].

Protein-protein interaction (PPI) inhibitors are an emerging topic in the field of drug development, including for targeting the DDR pathway, as illustrated by compounds disrupting the BRCA2-RAD51 and the MUS81-EME1 interactions [27, 28]. Recently, Ueno et al. developed TAS1553, a PPI disruptive agent targeting the RNR complex. TAS1553 binds to the C-terminus binding site of RRM1, thereby inhibiting the physical binding of RRM2 [29]. Given this specific mode of action, TAS1553 provides a unique entry point for more selective and direct RNR inhibition compared to the historical set of available drugs and could potentially reduce the resistance and toxicity observed using HU and 3-AP.

In the current study, we show that TAS1553 inhibits NB cell proliferation and induces RS, DNA damage and apoptosis. We benchmarked the molecular responses of TAS1553 single drug treatment and revealed a strong impact on RNA splicing. Second, in line with our previous work [7], we also demonstrate strong synergism between TAS1553 and the CHK1 inhibitors prexasertib and SRA737 in NB cell lines and tumoroids, with underlying gene signatures recapitulating our previously established gene signatures [7]. We confirmed these synergistic interactions *in vivo* using a zebrafish NB xenograft model and expanded the validity of these drug combinations *in vitro* towards pediatric sarcoma.

RESULTS

TAS1553 mediated RRM1-RRM2 disruption inhibits neuroblastoma cell growth and induces replicative stress, DNA damage and apoptosis

The phenotypic impact of TAS1553 treatment was assessed using a broad concentration range (0.5 μM –4 μM) in a panel of NB cell lines, including both *MYCN* amplified and non-amplified tumors. TAS1553 treatment induced a decrease in cell confluence in eight out of ten cell lines with IC_{50} -values in the low micromolar range (Fig. 1A), with no significant differential response profile between *MYCN* amplified and non-amplified cell lines. In addition to classical 2D cell lines, we could also show decreased cell viability upon treatment with TAS1553 in established tumoroid models and a patient-derived xenograft (PDX) tumoroid (Fig. 1B). In addition, TAS1553 also inhibits cell growth in a panel of pediatric sarcoma cell lines, including EWS, osteosarcoma and rhabdomyosarcoma (Supplementary Fig. S1A–C). Furthermore, we observed a cytotoxic effect of TAS1553 in NB cell lines through apoptotic cell death compared to DMSO controls, while only cytostatic effects were noted in the non-cancerous retinal pigment epithelial (RPE) cells, underscoring the on-target effect of TAS1553 in cancer cell lines (Fig. 1A, C). In line with our previous findings regarding RRM2 inhibition using 3-AP in NB [7], TAS1553 treatment resulted in increased RS levels and both single and double-stranded DNA breaks, represented by increased levels of ATR-induced pCHK1^{S345}, pRPA32^{S33}, and γH2AX (Fig. 1D, Supplementary Fig. S1D). We also noted a slight upregulation of RRM2 levels upon TAS1553 treatment (Supplementary Fig. S1D), which could point towards a compensatory upregulation of RRM2, as previously also reported for glioblastoma upon RRM2 inhibition [30]. Furthermore, induction of apoptosis was confirmed through the elevated protein levels of cleaved PARP (cPARP) and increased mRNA expression of the pro-apoptotic genes *BAX*, *PUMA* and *NOXA* (Fig. 1D, E). The expression of the p53 target genes *CDKN1A* and *RRM2B* was also upregulated following TAS1553 treatment (Fig. 1E). Functional inhibition of the RNR complex was validated by depletion of the dNTP pools after TAS1553 treatment (Fig. 1F). However, dTTP

levels were upregulated upon TAS1553 exposure in CLB-GA cells, whereas this was not observed in IMR-32. The RNR complex is required for the *de novo* dNTP synthesis, but not for the salvage pathway used to produce dTTP [31]. Altogether, our *in vitro* phenotypic response data support that TAS1553 negatively impacts on NB and sarcoma cell viability by enhancing RS, increasing DNA damage and inducing cell death.

TAS1553 treatment induces replication stress, apoptosis and immunomodulatory signatures in neuroblastoma

Transcriptome profiling following TAS1553 exposure revealed a robust set of differentially expressed genes in both the *MYCN* amplified as well as non-amplified NB cell lines IMR-32 and CLB-GA respectively (Fig. 2A and Supplementary Fig. S2A). Interestingly, one of the top ranked downregulated genes is *H1-0*, encoding the linker histone H1, with a key role in replication fork stability upon fork stalling [32]. Reduced expression of *H1-0* under therapeutic pressure suggests increased fork stalling and possible fork collapse, which induces cell death. Furthermore, genes involved in apoptosis (*CDKN1A*, *BBC3*, *TNFRSF10B*) and DNA damage (*PLK2*, *GADD45A*) were amongst the top-ranked upregulated genes in both IMR-32 and CLB-GA (Fig. 2A). Gene set enrichment analysis (GSEA) revealed on the one hand a significant upregulation of p53 target genes, including *HEXIM1* in IMR-32 as a negative regulator of the transcriptional regulator pTEFb [33] (Fig. 2B, C). Moreover, upregulation of TNF- α signaling via NF- κB and interferon alpha associated gene signatures can potentially be linked to an immunomodulatory drug response. On the other hand, *MYC* target genes, such as *CBX3*, implicated in replication fork stability [34], and G2M checkpoint related genes, including the NB core regulatory circuitry factor *MEIS2* [35], were amongst the top downregulated gene sets in IMR-32 (Fig. 2B, C). *MYC* target genes downregulated in CLB-GA included *HSP90AB1*, necessary for *MYCN* stabilization in NB [36] and the G2M checkpoint related gene *BIRC5*, which also has a previously described functional role in NB [37] (Supplementary Fig. S2B). This is all in accordance with our previously established 3-AP treated or siRNA mediated RRM2 knock-down transcriptome signatures in NB [7] (Fig. 2B, Supplementary Fig. S2C). Given that the clinical trials for 3-AP as RRM2 inhibitor were associated with major adverse effects, including methemoglobinemia, we propose TAS1553 as a potent alternative to be further investigated in extended preclinical testing and subsequent clinical trials.

Benchmarking the TAS1553-prexasertib drug synergism *in vitro* and *in vivo*

Following the validation of TAS1553 as a potent RRM2 inhibitor, we next evaluated whether TAS1553 treatment in combination with CHK1 inhibition using prexasertib also resulted in similar synergy as previously obtained with 3-AP [7]. To this end, we tested a broad concentration range of both compounds (0.06 μM –1.50 μM of TAS1553 and 0.1 nM–2 nM of prexasertib) and monitored cell confluence for 96 h via the IncuCyte Live Cell Imaging System (Fig. 3A, Supplementary Fig. S3A). Treatment with 0.88 μM TAS1553 and 0.74 nM prexasertib resulted in high bliss index (BI) scores of respectively 0.80 and 0.66 in IMR-32 and CLB-GA, indeed confirming strong synergism between TAS1553 and prexasertib. This combination treatment resulted in reduced cell confluence and increased caspase 3/7 levels reflecting apoptosis, compared to treatment with the same low-dose concentrations of the single agents or DMSO control treatment (Fig. 3A, Supplementary Fig. S3A). Furthermore, we evaluated the combination of TAS1553 and prexasertib in SK-N-AS and in the p53-mutant and therapy-resistant cell line SK-N-BE (2)-C and could show reduced cell confluency, concomitant with significant caspase 3/7 induction compared to controls, upon treatment with both TAS1553 and prexasertib (Supplementary Fig. S4A, B). In the non-cancerous RPE cells, only a slight reduction in cell confluence and no apoptotic effects were observed, suggesting on-




Fig. 1 TAS1553 reduces neuroblastoma cell growth and induces RS stress, DNA damage and apoptosis in vitro. **A** Dose-response curves following 96 h of TAS1553 exposure in a panel of NB cell lines, including 6 *MYCN* amplified (red) and 4 *MYCN* non-amplified (blue), and the nonmalignant RPE cell line (grey) using the IncuCyte® Live-Cell imaging. The IC₅₀ of each cell line is indicated between the brackets. Graphs represent the mean of 3-5 biological replicates in triplicate \pm standard error of the mean (SEM). **B** Dose-response curves following 120 h of TAS1553 exposure in a panel of NB tumoroids and their respective IC₅₀, including *MYCN* amplified (red) and *MYCN* non-amplified (blue). Cell viability was measured using the CellTiter-Glo® 3D Cell Viability Assay. *N* = 3 biological replicates in triplicate \pm SEM. **C** Caspase-Glo luminescence-based measurements of caspase 3/7 activity in IMR-32, CLB-GA and RPE following TAS1553 treatment for 48 h. Graphs represent the mean of 3 biological replicates in triplicate \pm SEM. **D** Representative immunoblotting data for various replicative stress and DNA damage markers in IMR-32 and CLB-GA following 48 h treatment with their respective IC₅₀ of TAS1553 (1.18 μM and 1.54 μM respectively). The quantification of all individual biological replicates is shown in Supplementary Figure S1D. **E** RT-qPCR based measurements of mRNA expression levels of the apoptotic genes *BAX*, *PUMA* and *NOXA*, and the *p53* target genes *CDKN1A* and *RRM2B* after treatment of IMR-32 (top) and CLB-GA (bottom) cell lines with their respective IC₅₀ of TAS1553 at 48 h. Graphs represent the mean of 4 biological replicates \pm SEM. Statistical significance was measured using the multiple unpaired T-test (* = $p \leq 0.05$, ** = $p \leq 0.01$, *** = $p \leq 0.001$). **F** dNTP pools are reduced in IMR-32 and CLB-GA upon treatment with the IC₅₀ of TAS1553 for 48 h. Statistical significance was measured using the unpaired T-test (* = $p \leq 0.05$, ** = $p \leq 0.01$, *** = $p \leq 0.001$, **** = $p \leq 0.0001$), error bars represent SEM.





Fig. 2 Benchmarking TAS1553 imposed transcriptional signatures in neuroblastoma. A Volcano plots of IMR-32 (*top*) and CLB-GA (*bottom*) of significantly differentially expressed genes (DEGs) following TAS1553 IC₅₀ exposure for 48 h (1.18 μ M and 1.54 μ M respectively). Genes indicated by name cover the top 15 DEGs. NS not significant. **B** Bubble plots of all overlapping Hallmark MSigDB gene sets significantly up or downregulated in IMR-32 or CLB-GA cells after treatment (48 h) with their respective IC₅₀ for TAS1553 (1.18 μ M and 1.54 μ M) (*left*) or 3-AP (0.69 μ M and 0.96 μ M) (*right*). **C** Detailed view of the GSEA enrichment for the p53 pathway, MYC targets and G2M checkpoint Hallmark MSigDB gene sets after treatment of IMR-32 with 1.18 μ M TAS1553 (IC₅₀) treatment (*left*) and heatmaps showing the top 50 genes within the core enrichment (*right*). ES enrichment score.



target toxicity (Supplementary Fig. S5A). Next to the classical 2D cell lines, we tested the combination in three established and one PDX derived NB tumoroid. Remarkably, we are able to show synergism in these tumoroids with BI scores in the same range as obtained in cell lines (Fig. 3B). In line with the increased caspase 3/7 activity in IMR-

32 and CLB-GA, mRNA expression of the pro-apoptotic genes *BAX*, *PUMA* and *NOXA* was upregulated following combination treatment while increased gene expression of *CDKN1A* and *RRM2B* indicates p53 pathway activation (Fig. 3C, Supplementary Fig. S3C). Immunoblotting showed elevated pCHK1^{S345}, pRPA32^{S33} and γ H2AX levels,

Fig. 3 Benchmarking TAS1553-prexasertib drug synergism in vitro and in vivo. **A** Heatmap showing the Bliss Index (BI) scores for IMR-32 after 96 h of treatment with a range of concentrations of TAS1553 and prexasertib. $N = 4$ biological replicates in duplicate (*left*). Cell confluency was monitored for 96 h and cells were treated with the concentrations with the highest BI score (0.74 nM prexasertib and 0.88 μM TAS1553). $N = 4$ biological replicates in duplicate, error bars represent SEM (*middle*). Caspase-Glo luminescence-based measurements of caspase 3/7 activity in IMR-32 following treatment with TAS1553 and prexasertib for 48 h. $N = 3$ biological replicates in triplicate, error bars represent SEM. Statistical significance was measured using one-way ANOVA followed by a Dunnett's multiple comparison test (**= $p \leq 0.01$, ****= $p \leq 0.0001$) (*right*). **B** Heatmaps showing the BI scores for established NB tumoroids MaxNB039, AMC691B and AMC772T, and PDX-derived NB tumoroid NEC0005 after 120 h of treatment with a range of TAS1553 in combination with prexasertib. $N = 3$ biological replicates performed in triplicate. **C** RT-qPCR based measurements of mRNA expression of apoptotic genes *BAX*, *PUMA* and *NOXA*, and the *p21* target genes *CDKN1A* and *RRM2B* after treatment of IMR-32 with the combination of TAS1553 (0.88 μM) and prexasertib (0.74 nM) that resulted in the highest synergy scores at 48 h. $N = 4$ biological replicates in duplicate. Statistical significance was measured using the one-way ANOVA followed by a Dunnett's multiple comparison test (**= $p \leq 0.001$, ****= $p \leq 0.0001$), error bars represent SEM. **D** Representative immunoblotting data for various replicative stress and DNA damage markers in IMR-32 following 48 h treatment with 0.74 nM prexasertib and 0.88 μM TAS1553. The quantification of all replicates ($N = 3$) is shown in Supplementary Figure S8A. **E** Representative immunoblotting data for p4E-BP1 and 4E-BP1 in IMR-32 following 48 h treatment with 0.74 nM prexasertib and 0.88 μM TAS1553. The quantification of all replicates ($N = 3$) is shown in Supplementary Figure S8B. **F** Representative image of zebrafish treated with DMSO ($N = 23$), 1 μM prexasertib ($N = 24$), 50 μM TAS1553 ($N = 23$) or 1 μM prexasertib and 50 μM TAS1553 ($N = 21$). Cleaved caspase 3 (CC3) is shown in green and Hoechst in grey, scale bar represents 50 μm (*left*). Boxplot showing increased CC3 levels in SK-N-AS NB cells injected in zebrafish after 96 h of treatment with 1 μM prexasertib and 50 μM TAS1553 (*right*). Statistical significance was measured using the one-way ANOVA followed by a Dunnett's multiple comparison test (*= $p \leq 0.05$, ****= $p \leq 0.0001$), error bars represent min and max and average is shown.

indicating increased RS levels and DNA damage induction. In addition, we observed downregulation of pCHK1^{S296} (CHK1 autophosphorylation site) and total CHK1 levels (Fig. 3D, Supplementary Figs. S3D, S8A). This is in line with previous studies showing that functional inhibition or knockdown of RRM2 directly affects protein translation through inhibition of the translational inhibitor 4E-BP1 [38]. Indeed, we confirmed a downregulation of p4E-BP1 and total 4E-BP1 protein levels (Fig. 3E, Supplementary Figs. S3E, S8B). Furthermore, elevated cPARP levels confirmed the observed apoptosis induction in NB cells treated with the combination compared to single agent or DMSO control treatment conditions (Fig. 3D, Supplementary Figs. S3D, S8A). Next, we also confirmed this synergistic interaction in a panel of pediatric sarcoma cell lines including one EWS, one osteosarcoma and two rhabdomyosarcoma lines (Supplementary Fig. S6A–C), showing therapeutic value for this combination treatment in other pediatric entities beyond NB.


To assess the in vivo efficacy of combined TAS1553 and prexasertib treatment, we utilized a zebrafish NB xenograft model using the SK-N-AS cell line, given its well-established engrafting potential [39]. With regards to in vivo drug responses, we first determined the maximum non-toxic dose (MNTD) by testing a concentration range of TAS1553 and prexasertib on wild-type 3-days-old zebrafish. Zebrafish tolerated combined treatment with 50 μM of TAS1553 and 2.5 μM of prexasertib without any apparent signs of toxicity (such as cardiac oedema or curved tails) (Supplementary Fig. S7A). Next, SK-N-AS cells were injected into the perivitelline space of 2-days-old zebrafish and treated for 96 h with the respective MNTD of both compounds and stained them for CC3, a marker of apoptosis. However, we reduced the prexasertib concentration to 1 μM to achieve synergism between prexasertib and TAS1553 in the zebrafish xenograft model. Combination treatment with 1 μM prexasertib and 50 μM TAS1553 resulted in an average increase of approximately 9 K and 25 K CC3+ cells per mm^3 tumor compared to prexasertib or TAS1553 monotherapy respectively, indicating a substantial increase of apoptosis (Fig. 3F), in line with our findings in vitro.

Expanding the combinatorial RRM2-CHK1 drugging with TAS1553 and the selective CHK1 inhibitor SRA737

Given that prexasertib also substantially inhibits CHK2 [40], we next assessed combinatorial treatment of TAS1553 with SRA737, which has been shown to target CHK1 with a 1,000-fold greater selectivity over CHK2 [41]. We observed higher BI scores for TAS1553-SRA737 drugging (up to 0.84 in IMR-32 and 0.70 in CLB-GA) (Fig. 4A, Supplementary Fig. S3B), compared to the combination of TAS1553 and prexasertib (0.80 and 0.66 in IMR-32 and CLB-GA respectively). Moreover, these high BI scores were achieved

with lower concentrations of TAS1553 (0.88 μM in combination with prexasertib versus 0.51 μM in combination with SRA737). Next, we also tested this combination in NB tumoroids, and achieved BI scores ranging between 0.29 and 0.69, demonstrating drug synergism in the tumoroids as well (Fig. 4B). In addition, we show reduced cell confluency and significant induction of apoptosis upon treatment with TAS1553 and SRA737 in SK-N-AS and in the p53-mutant and therapy-resistant cell line SK-N-BE(2)-C (Supplementary Fig. S4C, D). This indicates that this combination is also effective in therapy resistant tumors. These strong synergistic effects were again confirmed in a panel of pediatric sarcoma cell lines of EWS, osteosarcoma and rhabdomyosarcoma, while not affecting the non-cancerous RPE cells, showing on-target toxicity (Supplementary Fig. S5B, S6D–F). The reduced confluency was again accompanied by an increase in apoptosis, specifically in the cancer cell lines and not in the non-cancerous RPE cells (Fig. 4A, Supplementary Fig. S3B, S5B), which was further validated through elevated mRNA expression of the pro-apoptotic markers *BAX*, *PUMA*, and *NOXA* and the p53 target genes *CDKN1A* and *RRM2B* using RT-qPCR, as well as increased levels of cPARP by immunoblotting (Fig. 4C, D, Supplementary Fig. S3C, D). Moreover, the TAS1553-SRA737 combination treatment resulted in reduced pCHK1^{S296}, total CHK1, total RPA and RRM2 levels, together with concomitant upregulation of pCHK1^{S345}, pRPA32^{S33} and γH2AX levels reflecting increased RS and DNA damage (Fig. 4D, Supplementary Figs. S3D, S8C). In contrast to the combination with prexasertib, we do observe a significant depletion of RRM2 protein levels upon exposure to TAS1553 in combination with SRA737 in IMR-32. In line with previous findings, this can be related to a decrease in p4EBP1 levels upon RRM2-CHK1 inhibition [38] (Fig. 4E, Supplementary Figs. S3E, S8D), concomitant with a reduction of total RPA, CHK1 and RRM2 protein levels, in parallel to their pharmacological inhibition. This effect may be more pronounced with SRA737 given its higher selectivity for CHK1 compared to prexasertib. Both SRA737 low dose single agent treatment and its combination with low dose TAS1553 effectively reduced CHK1 auto-activation, as indicated by downregulated levels of pCHK1^{S296} compared to TAS1553 (low dose) single or control (DMSO) treatment.

Next, we defined 25 μM SRA737 combined with 100 μM TAS1553 as the MNTD of this combination treatment in SK-N-AS xenografted zebrafish (Supplementary Fig. S7B). The concentration of the SRA737 was lowered to 15 μM to achieve synergism with 100 μM TAS1553 in the zebrafish xenografts. Combination treatment resulted on average in approximately 21 K and 37 K additional CC3+ cells per mm^3 tumor as compared to SRA737 and TAS1553 monotherapy respectively and 40 K additional CC3+ cells



per mm³ tumor as compared to the DMSO control (Fig. 4F). Collectively, these results indicate that TAS1553 and SRA737 are potent next-generation inhibitors that open a novel avenue for combined selective RRM2-CHK1 inhibition in NB and pediatric sarcomas.

Combined RRM2-CHK1 inhibition leads to differential expression of MYC(N) and ALK-controlled gene signatures
In the next step, we scrutinized the molecular consequences imposed by either TAS1553-prexasertib or TAS1553-SRA737 drugging, showing a clear and robust transcriptional effect of

Fig. 4 Scrutinizing selective CHK1 inhibition using SRA737 as novel synergistic entry point with TAS1553. **A** Heatmap showing the bliss index (BI) scores for IMR-32 after 96 h of treatment with a range of concentrations of TAS1553 and SRA737. $N = 5$ biological replicates in duplicate (left). Cell confluency was monitored for 96 h and cells were treated with the concentrations with the highest BI score (0.28 μM SRA737 and 0.51 μM TAS1553). $N = 5$ biological replicates in duplicate, error bars represent SEM (middle). Caspase-Glo luminescence-based measurements of caspase 3/7 activity in IMR-32 following treatment with TAS1553 and SRA737 for 48 h. $N = 3$ biological replicates in triplicate, error bars represent SEM. Statistical significance was measured using the one-way ANOVA followed by a Dunnett's multiple comparison test (**** = $p \leq 0.0001$) (right). **B** Heatmaps showing the BI scores for established NB tumoroids MaxNB039, AMC691B and AMC772T, and PDX-derived NB tumoroid NEC0005 after 120 h of treatment with a range of TAS1553 in combination with SRA737. $N = 3$ biological replicates in triplicate. **C** RT-qPCR based measurements of mRNA expression of the apoptotic genes *BAX*, *PUMA* and *NOXA*, and the *p21* target genes *CDKN1A* and *RRM2B* after treatment of IMR-32 with the best combination of TAS1553 (0.51 μM) and SRA737 (0.28 μM) that resulted in the highest synergy scores at 48 h. $N = 4$ biological replicates in duplicate. Statistical significance was measured using the one-way ANOVA followed by a Dunnett's multiple comparison test (**** = $p \leq 0.0001$), error bars represent SEM. **D** Representative immunoblotting data for various replicative stress and DNA damage markers in IMR-32 following treatment with 0.28 μM SRA737 and 0.51 μM TAS1553 for 48 h. The quantification of all replicates ($N = 3$) is shown in Supplementary Figure S8C. **E** Representative immunoblotting data for p4E-BP1 and 4E-BP1 in IMR-32 following treatment with 0.28 μM SRA737 and 0.51 μM TAS1553 for 48 h. The quantification of all replicates ($N = 3$) is shown in Supplementary Figure S8D. **F** Representative image of zebrafish treated with DMSO ($N = 19$), 15 μM SRA737 ($N = 18$), 100 μM TAS1553 ($N = 17$) or 15 μM SRA737 and 100 μM TAS1553 ($N = 22$). Cleaved caspase 3 (CC3) is shown in green and Hoechst in grey, scale bar represents 50 μm (left). Boxplot showing increased CC3 expression in SK-N-AS NB cells injected in zebrafish after 96 h of treatment with 15 μM SRA737 and 100 μM TAS1553 (right). Statistical significance was measured using the Welch's ANOVA followed by a Dunnett's multiple comparison test (*** = $p \leq 0.001$, **** = $p \leq 0.0001$), error bars represent min and max and average is shown.

the combination treated samples compared to single treatment and DMSO treatment (Supplementary Fig. S9A, B). As anticipated, genes involved in cell death (*CDKN1A*, *BBC3*, *BAX*) and DNA damage (*PLK2*, *GADD45A*) were amongst the top-ranked upregulated genes in both IMR-32 and CLB-GA. Furthermore, the expression of *MDM2*, is upregulated after treatment, which might result from counteracting the reduction in *p53* pathway activity [42] (Fig. 5A, B). Similarly to our previously published transcriptome data [7], GSEA pointed towards significant downregulation of G2M checkpoint genes, E2F targets, and MYC targets while *p53* pathway signature genes are upregulated (Fig. 5C). Moreover, we identified a strong overlap in transcriptional profiles between the different combinations of RRM2 and CHK1 inhibitors evaluated in this study (Fig. 5D, Supplementary Fig. S9C). Additionally, we performed GSEA using our different RRM2-CHK1 combination datasets by means of a custom compiled set of publicly available gene signatures (Fig. 5E). This analysis confirmed significant downregulation of MYCN-driven targets in all drug combinations included in our study [43]. This corresponds to the downregulation of MYCN protein levels upon treatment with TAS1553 and prexasertib or SRA737 (Fig. 5F, Supplementary Fig. S9D, S8B, D). Furthermore, we observed a downregulation of the pan-cancer prexasertib response signature [4] and a gene signature associated with elimusertib mediated ATR inhibition in NB [5]. Interestingly, genes activated by ALK signaling are upregulated [44]. These findings suggest that the RRM2-CHK1 inhibition treatment could be further potentiated with pharmacological ATR or ALK inhibition which should be further evaluated. Finally, we could show that adrenergic markers were downregulated upon combined RRM2-CHK1 inhibition [45] (Fig. 5E).

TAS1553 treatment downregulates expression of key RNA splicing components

The majority of gene signatures associated with the molecular response to RRM2-CHK1 inhibitors included in this study show a significant overlap (Fig. 2B and Fig. 5C). However, we observed selective enrichment of gene sets comprising core spliceosome encoding genes specifically in TAS1553 single treatment conditions (I_{C50}) and in combination with CHK1 inhibition (Fig. 6A, Supplementary Fig. S10A). This signature includes amongst others the small nuclear ribonucleoprotein (snRNP) U1 and U5 (Fig. 6B). U1 snRNP recognizes the 5' splicing site (5' SS) and is necessary to initiate the splicing process via the spliceosome [46] and U5 snRNP interacts with U4/U6 to form the complete spliceosome complex and start the branching and exon ligation steps [47]. Furthermore, *Prp43*, involved in the disassembly of the spliceosome, is also downregulated, suggesting a depletion of U2/U5/U6







to form new spliceosomes (Fig. 6B). Indeed, previous studies have indicated a functional interconnection between pre-mRNA processing and RS [48, 49]. It can therefore be anticipated that TAS1553 could also act synergistically with splicing inhibitors and should be further investigated in follow-up of this study.

DISCUSSION

We evaluated the in vitro and in vivo phenotypic consequences of selective RNR inhibition through disruption of the RRM1-RRM2 complex using the novel TAS1553 inhibitor [29]. At the molecular level, TAS1553 treatment induced elevated levels of RS and DNA damage and showed synergism with the CHK1 inhibitors prexasertib and SRA737. We were able to show for both drug combinations significant synergistic interactions in in vitro and in vivo models. Interestingly, transcriptome analysis revealed that TAS1553, either as single agent or in combination with CHK1 inhibition, results in selective downregulation of gene sets related to RNA splicing components.

We and others previously reported on the dependency role of RRM2 in tumorigenesis, establishing it as an attractive therapeutic target for extensive drug development efforts [7, 11, 13, 17]. First-generation RRM2 inhibitors included hydroxyurea (HU) and 3-AP. In short, HU acts as radical scavenger and was approved by the Food and Drug Administration (FDA) for treatment of sickle cell disease and myeloid neoplasms [50, 51]. However, HU has a short half-life in humans and tumor cells acquire resistance to HU via increased expression of RRM2 [52, 53]. In contrast, 3-AP is an iron chelator [22, 24] and is able to overcome this resistance [54], but further clinical development efforts have been halted. The RRM1 inhibitor gemcitabine is a nucleoside analog for dCTP and can bind to the catalytic site of RRM1 [55–57]. However, RRM1 is expressed throughout the cell cycle, while RRM2 expression is induced in early S-phase and rapidly degraded upon S-G2 phase transition [58]. Therefore, RRM2 is the rate limiting factor of the RNR complex and considered the most clinically relevant RNR target protein. Next-generation and more on-target RRM2 inhibitors were considered to be required to overcome therapy resistance and decrease the number of adverse events. In this respect, Ueno and colleagues developed TAS1553 which specifically disrupts the interaction between RRM1 and RRM2 [29].

In addition, tumor cells rapidly acquire resistance against single-compound treatment regimens [59]. Therefore, we aimed to evaluate both TAS1553 as single agent and in combination with the CHK1 inhibitors prexasertib and SRA737 in this study, the latter two being ATP-competitive CHK1 protein kinase inhibitors.



Notably, synergistic interactions with SRA737 could be achieved with a lower input concentration of TAS1553 compared to the combination with prexasertib. This could be due to the stronger selectivity of SRA737 for CHK1 compared to prexasertib (1000-fold greater selectivity) [40, 41]. However, this selectivity profile was

determined by in vitro kinase assays. Interestingly, a study by Ditano et al. compared the CHK1 versus CHK2 selectivity of prexasertib versus SRA737 [60] and suggests that the prexasertib concentrations used in our study do not affect CHK2, therefore implying that presumed selectivity for CHK1 over CHK2 of SRA737

Fig. 5 Benchmarking gene expression signatures following TAS1553 exposure in combination with either SRA737 or prexasertib. **A** Volcano plots of IMR-32 (*top*) and CLB-GA (*bottom*) of significantly DEGs after treatment with 0.74 nM prexasertib and 0.88 μ M TAS1553 for 48 h. Genes indicated by name cover the top 15 DEGs. NS not significant. **B** Volcano plots of IMR-32 (*top*) and CLB-GA (*bottom*) of significantly DEGs after treatment with 0.28 μ M SRA737 and 0.51 μ M TAS1553 for 48 h. Genes indicated by name cover the top 15 DEGs. NS= not significant. **C** Bubble plot showing the top gene sets enriched after the indicated combination treatment for 48 h for IMR-32 and CLB-GA. **D** GSEA of the RNA-seq based transcriptome profiles following combined drug treatment with TAS1553 and prexasertib (*left*) or TAS1553 and SRA737 (*right*) in IMR-32 cells showing a significant overlap between genes enriched upon combination treatment of TAS1553 with prexasertib, TAS1553 with SRA737 or 3-AP with prexasertib. **E** Heatmap showing the NES scores from our different combination treatments compared to publicly available gene sets [4, 5, 43–45]. **F** Representative immunoblotting data for MYCN in IMR-32 following 48 h treatment with 0.74 nM prexasertib and 0.88 μ M TAS1553 or 0.28 μ M SRA737 and 0.51 μ M TAS1553. The quantification of all replicates ($N = 3$) is shown in Supplementary Figure S8B, D.

does not explain the observed stronger synergistic interaction of TAS1553 with SRA737 versus prexasertib.

Pharmacological targeting of the RS and DNA damage response pathway results in fork collapse and double-stranded DNA breaks, resulting in release of double-stranded DNA into the cytosol, which can lead to activation of cGAS-STING pathway as previous studies shown using PARP inhibitors [61, 62]. More recently, the study of Taniguchi et al. showed activation of cGAS-STING following ATR inhibition in small-cell lung cancer via DNA damage mediated micronuclei [63]. While NB tumors are classified as immunologically 'cold' tumors [64], we showed that combined RRM2-CHK1 inhibition resulted in a significant upregulation of genes involved in inflammatory and interferon alpha responses. Therefore, this could be a promising entry point to sensitize NB tumors for immune checkpoint inhibitors.

Notably, we also identified that TAS1553 exposure imposes a significant downregulation of RNA splicing, and previous studies indeed support functional interaction between genomic stability and pre-mRNA processing. In this respect, it has been shown that DNA damage signaling, amongst others via ATR, can regulate splicing events via perturbed acetylation or phosphorylation of splicing factors [48]. On the other hand, downregulation of genes involved in mRNA processing results in increased levels of γ H2AX [49]. Here, treatment with TAS1553 leads to selective downregulation of genes necessary to form small nuclear ribonucleoproteins (snRNP; U1, U2, U4, U5, and U6). Previous studies have indeed shown that mutated U2 snRNP results in an increase of numbers of R-loops [65, 66] and that depletion of the U2 snRNP leads to decreased expression of the DDR factors RAD51, ATM and CHK1 [65]. One of the genes downregulated after TAS1553 treatment in the U2 snRNP complex is *SF3B1*. *SF3B1* is one of the core complexes of the U2 snRNP complex and is a druggable target in the spliceosome [67]. Interestingly, RNAi screening data of the DepMap initiative (Broad Institute, depmap.org) point towards *SF3B1* as selective NB dependency compared to other solid pediatric tumor entities (Supplementary Fig. S10B). Since TAS1553 decreases the expression of core splicing genes, we anticipate that pharmacological *SF3B1* inhibition could act synergistically with TAS1553 and should be further investigated in follow-up of this study.

While this study provides valuable insights, we acknowledge that there are some limitations to this study. The zebrafish xenograft model was established using one NB cell line and, even though it allows for drug toxicity and efficacy testing in an in vivo setting, zebrafish xenografts may not fully capture the complex biology and tumor microenvironment of a patient tumor.

In conclusion, we show that the RNR disruptive agent TAS1553 is a potent novel therapeutic entry point for NB and pediatric sarcoma, as single agent and in combination with CHK1 inhibition, both in vitro and in vivo in a NB zebrafish xenograft model. Future studies should consider to exploit combined RRM2-CHK1 inhibition for immunomodulation in NB and we recommend TAS1553 as potent entry point for novel synergistic drug interactions with splicing inhibitors for pediatric solid tumor entities.

MATERIALS AND METHODS

Cell culture

The human NB cell lines CLB-GA, SK-N-AS, SH-SY5Y, SH-EP, CHP-212, IMR-32, N206, NGP, SK-N-BE(2)-C, and TR14 were cultured in RPMI1640 (Gibco #52400041), supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich #F0804), 2mM L-glutamine (Gibco #11500626) and 100 IU/mL penicillin/streptomycin (Gibco #11548876). RPE cells were cultured in DMEM-F12 (Gibco #11594426), supplemented with 10% FBS, 2 mM L-glutamine, and 100 IU/mL penicillin/streptomycin. Human Ewing sarcoma (EWS) cell lines A-673, ES7, EW-7, MHH-ES-1, TC-71 and human osteosarcoma cell lines CAL-72, HS-Os-1, HuO9, MG-63, SaOs-2, U2OS were maintained in RPMI1640 medium with stable glutamine (Sigma-Aldrich #R8758) supplemented with 10% tetracycline-free FBS (Sigma-Aldrich #F7524), 100 IU/mL penicillin and 100 μ g/mL streptomycin (Sigma-Aldrich #P4333). The human rhabdomyosarcoma (RMS) cell lines Rh41 and RMS-YM were cultured in RPMI1640 (Gibco #52400041), supplemented with 10% FBS (Tico #FBSEU500), 2 mM L-glutamine (Gibco #11548876) and 100 IU/mL penicillin/streptomycin (Gibco #11548876). The human RMS cell lines RD, Rh30 and RMS-1 were cultured in DMEM (Gibco #41965-039), supplemented with 10% FBS (Tico #FBSEU500), 0.1 mM non-essential amino acids (NEAA) (Gibco #12084947), 2mM L-glutamine (Gibco #11500626) and 100 IU/mL penicillin/streptomycin (Gibco #11548876). All cells were incubated at 37 °C and 5% CO₂. All cells were tested for mycoplasma on regular basis and short tandem repeat (STR) genotyping is available. Cell line characteristics can be found in Supplementary Tables S1, S2, S3 and S4.

Generation of PDX derived tumoroids

The PDX line NEC0005 was kindly given to us in collaboration with the Experimental Pharmacology and Oncology (EPO) lab (Berlin, Germany) (Internal reference: EC19/1428). The tumoroid was established through mechanical and enzymatic dissociation of the solid tumor tissue. Freshly harvested PDX tumor tissue was aseptically minced into small fragments of 1 mm³ using sterile scalpels. The fragmented tissue was transferred to a tube containing Liberase DL digestion buffer (Liberase DL at 0.1 mg/mL (Roche #5466202001)), 100 U/mL DNase (Stemcell Technologies #07469), 20 mM HEPES (Gibco #15630056), and 1 mM CaCl₂ (Sigma-Aldrich #21097) in DMEM low glucose (Gibco #21885-025) and incubated for 30 minutes at 37 °C. The tube was swirled every 5 min. The resulting suspension was centrifuged at 300 g for 2 min. The supernatant containing a fraction of dissociated cells was carefully collected and filtered through a 70 μ m cell strainer. The remaining pellet was resuspended in Liberase TM buffer (Liberase TM at 0.1 mg/mL (Roche #5401119001)), 100 U/mL DNase (Stemcell Technologies #07469), 20 mM HEPES (Gibco #15630056), and 1 mM CaCl₂ (Sigma-Aldrich #21097) in DMEM low glucose (Gibco #21885-025) and a second round of digestion was carried out for an additional 30 min at 37 °C. The entire suspension was passed through a fresh 70 μ m cell strainer. The filtered cell suspensions from both digestion steps were spun down (5 min, 300 g, 4 °C). The cell pellets were gently resuspended in red blood cell lysis buffer (Roche #11814389001) and incubated for 4 min to remove erythrocytes. The lysis reaction was neutralized by adding DMEM low glucose (Gibco #21885-025). The cells were washed once, followed by centrifugation (5 min, 300 g, 4 °C). The dissociated tumor cells were resuspended in NB tumoroid medium (NBOM).

Tumoroid culture

The human NB tumoroids MaxNB039, AMC772T, AMC691B [68] and NEC0005 were cultured in NBOM, which consists of DMEM + GlutaMAX (Gibco #21885-025), and is supplemented with 20% Ham's F-12 nutrient




Fig. 6 TAS1553 induces downregulation of genes encoding splicing pathway components. **A** Bubble plot showing significant downregulation of gene sets involved in RNA splicing upon treatment for 48 h with RRM2 inhibitors alone or in combination with CHK1 inhibitors in IMR-32 (left). Corresponding GSEA of two gene sets involved in RNA splicing (top) or the spliceosome (bottom) after treatment with IC_{50} of TAS1553 in IMR-32 (right). **B** KEGG pathway analysis of the spliceosome in IMR-32 indicating which genes are significantly differentially expressed (blue: downregulated by TAS1553; red: upregulated by TAS1553) upon treatment with the IC_{50} of TAS1553 for 48 h.

mix + GlutaMAX (Gibco, #31765-027), 100IU/mL penicillin and 100IU/mL streptomycin (Gibco #11548876), 2% B-27 without vitamin A (Gibco #12587010), 1% N2 supplement (Gibco #15410294), 20 ng/mL epithelial growth factor (hEGF) (Gibco #AF-100-15), 40 ng/mL fibroblast growth factor basic (hFGF) (Genscript #Z03116), 200 ng/mL human insulin-like growth factor 1 (hIGF1) (Gibco #100-11-B) and 10 ng/mL human platelet derived growth factor (hPDGF) AA (Gibco #AF-100-13A) and BB (Gibco #AF-100-14B). All tumoroids were incubated at 37 °C and 5% CO_2 . Tumoroid characteristics can be found in Supplementary Table S5.

Compounds

TAS1553 (#HY-150785) and prexasertib (#HY-18174A) were purchased via Bio-Connect. SRA737 (#S8253) was purchased via Selleckchem.

Cell confluency assay

NB cell lines were seeded in 384-well plates at a density ranging from 1500–6000 cells/well and allowed to adhere overnight. RPE cells were seeded at a density of 200 cells/well. RMS cell lines were seeded at a density of 1000–3000 cells/well. Compounds were added in a concentration range to the plates using the Tecan D300e Digital Dispenser. Each experiment was performed with three technical replicates and at least three biological replicates were collected. The cells were monitored over time in the IncuCyte Live Cell Imaging System for at least 96 h. Each image was analyzed through the IncuCyte Software and cell proliferation was determined by the area (percentage of confluence) of cell images over time. Cell confluency was normalized to the DMSO control at 72 h or 96 h and the IC_{50} was determined using HTSplotter [69]. Graphs were made using GraphPad (version 10.3.1) and dose-response curves were determined using the

variable slope (four parameters) equation. The error bars indicate standard error of the mean (SEM) of at least three biological replicates.

Cell viability assay

EWS or OS cell lines were seeded in a 96-well plate at a density ranging from 1000–5000 cells/well and allowed to adhere overnight. Compounds were serially diluted and added to the plates in a total volume of 100 μ L with at least three technical replicates. Cell viability was assessed 72 h after the treatment start with Resazurin cell viability assays (16 μ g/mL, Sigma-Aldrich). Dose response curves were simulated by nonlinear regression models using the variable slope equation and IC_{50} values were calculated using GraphPad (version 10.3.1) by normalizing to the respective controls (vehicle alone).

NB tumoroids were dissociated with accutase (Gibco #A11105) to obtain a single-cell suspension. After neutralization, cell viability was assessed using Trypan Blue prior to plating in 384-well plates at a density ranging from 5000–7000 cells/well. TAS1553 was dispensed in a concentration range to the plates using the Tecan D300e Digital Dispenser. Each experiment was performed with three technical replicates and three biological replicates were collected. Cell viability was assessed 120 h post-treatment with the CellTiter-Glo[®] 3D Cell Viability Assay (Promega #G9682) and luminescence was quantified using the GloMax[®] Discover Microplate Reader (Promega). The manufacturer's protocol was adapted, by adding 25 μ L of reagent to 50 μ L medium per well. Dose response curves were simulated by nonlinear regression models using the variable slope equation and IC_{50} values were calculated using GraphPad (version 10.3.1) by normalizing to the respective controls.

dNTP analysis

IMR-32 and CLB-GA cells were seeded at a density of 3×10^5 and 5×10^5 cells respectively in a 6-well plate and allowed to adhere overnight. The following day, medium was refreshed with medium supplemented with the compounds or medium only and again incubated for 48 h. Before harvesting, the medium was collected, plates were put on ice and cells were washed with 1 mL fresh prepared ice-cold 0.9% NaCl. Next, extraction buffer (80% methanol supplemented with 1 μ M d27 myristic acid, 3 μ M d7-15N4 arginine, 3 μ M 13C5-d5-15N glutamic acid and 3 μ M d12 glucose) was added and incubated on ice for 3 min. This was followed by scraping the cells and samples were stored overnight at -80°C . The next day, samples were centrifuged for 5 min, 20,000 g at 4°C . The supernatant was collected and sent for dNTP analysis. The cell pellets were stored at -80°C to determine the protein concentrations. Cell pellets were lysed in 200 μ L 200 mM NaOH and heated to 95°C for 20 min. Next, samples were centrifuged for 10 min, 6000 g at 4°C and the supernatant was collected. Protein concentrations were determined using the Pierce[™] BCA Protein Assay Kit (ThermoFisher #23227).

Combination and synergism measurements

CLB-GA, IMR-32, SK-N-AS and SK-N-BE(2)-C were seeded in 384-well plates at a density ranging from 1000 to 2400 cells/well and allowed to adhere overnight. The RMS cell lines Rh30 and RM-SYM were seeded at a density ranging from 1500 to 3000 cells/well and allowed to adhere overnight. The following day, cells were treated with the respective compounds alone or in a combination matrix using the Tecan D300e Digital Dispenser. Each experiment was performed with two technical replicates. The cells were monitored over time in the IncuCyte Live Cell Imaging System for at least 96 h. Each image was analyzed through the IncuCyte Software and cell proliferation was determined by the area (percentage of confluence) of cell images over time. Synergism was determined using the Bliss Index (BI) score as identified by HTSplotter [69]. Each experiment was repeated 3–5 times to determine the combination with the highest BI score. Confluency graphs were made using GraphPad (version 10.3.1). The error bars indicate SEM.

NB tumoroids were dissociated with accutase (Gibco #A11105) to obtain a single-cell suspension. After neutralization, cell viability was assessed using Trypan Blue prior to plating in 384-well plates at a density ranging from 5000 to 7000 cells/well. Compounds were dispensed in a concentration matrix or alone to the plates using the Tecan D300e Digital Dispenser. Each experiment was performed with three technical replicates, and three biological replicates were collected. Cell viability was assessed 120 h post-treatment with the CellTiter-Glo[®] 3D Cell Viability Assay (Promega #G9682) and luminescence was quantified using the GloMax[®] Discover Microplate Reader (Promega). The manufacturer's protocol was adapted, by adding

25 μ L of reagent to 50 μ L medium per well. Synergism was determined using the BI score as identified by SynergyFinder [70].

For EWS, A-673 and E57, cells were seeded in a 96-well plate in triplicate at a density of 2500 cells/well and 1500 cells/well, respectively, and allowed to adhere overnight. The following day, cells were treated with the indicated drug combinations in three serial doses (4×4 matrices). Cell viability was assessed with Resazurin cell viability assays 72 h after the treatment start and values were normalized to the respective controls (vehicle alone). Synergism was determined using the BI score as identified by SynergyFinder [70].

For OS, MG-63 and U2OS cells were seeded in a 96-well plate in duplicate at a density of 1000 cells/well and 1500 cells/well, respectively, and allowed to adhere overnight. The following day, cells were treated with various drug combinations in five serial doses (6×6 matrices). Cell viability was assessed with Resazurin cell viability assays 72 h after the treatment start and values were normalized to the respective controls (vehicle alone). Synergism was determined using the BI score as identified by SynergyFinder [70].

Apoptosis assay

CLB-GA (15,000 cells/well), IMR-32 (14,000 cells/well), SK-N-AS (15,000 cells/well), SK-N-BE(2)-C (5000 cells/well) and RPE (2000 cells/well) were seeded in a 96-well plate and allowed to adhere overnight. The next day, cells were treated with the designated compounds using the Tecan D300e Digital Dispenser and put in the incubator. Pictures were taken 0 h, 24 h and 48 h after treatment with the IncuCyte Live Cell Imaging System to follow cell growth. After 48 h, apoptosis levels were measured using the Caspase-Glo 3/7[®] Assay (Promega #G8091). The manufacturer's protocol was adapted by adding 50 μ L of reagent to 100 μ L medium per well. Each experiment included three technical replicates. The average luminescence of the treated wells was scaled to the DMSO control. Graphs were made using GraphPad (version 10.3.1), and error bars represent the SEM of three biological replicates. Statistical significance was determined using the one-way ANOVA followed by a Dunnett's multiple comparison test.

Protein isolation

IMR-32 and CLB-GA cells were seeded in T25 culture flasks (Greiner #690175) at a density of 0.8×10^6 and 1×10^6 cells respectively and allowed to adhere for 48 h. After 48 h, medium was refreshed with medium supplemented with DMSO, the compounds or medium only and again incubated for 48 h. Next, cells were harvested using a cell scraper and ice-cold phosphate buffered saline (PBS, Gibco #14190094), and centrifuged for 5 min, 2500 rpm, at 4°C . This was followed by a wash in PBS and again centrifuged for 5 min, 2500 rpm, at 4°C . Cell pellets were snap frozen in liquid nitrogen after centrifugation.

Next, cell pellets were lysed in cold RIPA buffer (250 mg sodium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.01% SDS solution, 0.1% NP-40), supplemented with protease (Roche #11836145001) and phosphatase (Roche #04906845001) inhibitors. This was followed by rotation at 4°C for 1 h to achieve more complete lysis. Next, samples were centrifuged for 10 min, 10,000 rpm, at 4°C , and the lysates were collected. Protein concentrations were determined using the Pierce[™] BCA Protein Assay Kit (ThermoFisher #23227).

Western blotting

Prior to gel loading, 30 μ g of protein was denatured by adding 5x Laemmli denaturation buffer supplemented with β -mercaptoethanol, and heated to 95°C for 10 min. Next, samples were loaded on 10% SDS-PAGE gels with 10x Tris/glycine/SDS buffer (Bio-Rad #1610772) and run for 1 h at 130 V. This was followed by blotting on nitrocellulose membranes in 10% of 10x Tris/Glycine buffer (Bio-Rad #1610771) and 20% methanol, for 1 h at 100 V. Ponceau staining was used to confirm the protein transfer. Membranes were blocked in 5% milk or 5% BSA (Sigma-Aldrich #A7030) in TBS-T for 1 h at room temperature (RT). Primary antibodies were diluted in their respective blocking buffer and membranes were incubated overnight at 4°C . The next day, blots were washed 3x for 5 min with TBS-T followed by 1 h incubation of the secondary antibodies at RT. Subsequently, blots were washed again 3x for 5 min with TBS-T. The immunoblots were visualized on the Amersham[™] Imager 680, using the enhanced chemiluminescent West Femto (Thermo Scientific #34096) or West Dura (Fisher Scientific #10220294). To visualize additional antibodies, blots were stripped using the Restore[™] Stripping Buffer (Thermo Scientific #10016433). The antibody information can be found in

Supplementary Table S7. Full and uncropped western blots can be found in the Supplemental Material. Quantification analysis was performed through ImageJ software (version 2.14.0). Fold changes were scaled to vinculin or their corresponding total protein. Graphs were made using GraphPad (version 10.3.1), error bars represent the standard deviation of three biological replicates, and statistical analysis was performed using the unpaired T-test for the single-treated experiments and one-way ANOVA followed by a Dunnett's multiple comparison test for the combination.

Simple Western

Simple Western was performed using the Wes instrument (Bio-Techne) [71]. The 12–230 kDa Wes Separation module (Bio-Techne #SM-W004) and EZ standard pack (Bio-Techne #PS-ST01EZ-8) were used to load the lysates. Lysates were loaded at a concentration of 0.2 µg/µL for MYCN or 0.8 µg/µL for p4E-BP1 and 4E-BP1. The antibody information can be found in supplementary table S7. Quantification analysis was done using the chemiluminescence peaks generated in the Compass for Simple Western software (version 6.1.0). The area under the curve (AUC) was calculated according to the dropped lines fit method. Fold changes were scaled to vinculin or their corresponding total protein. Graphs were made using GraphPad (version 10.3.1), error bars represent the standard deviation of three biological replicates and statistical analysis was performed using the unpaired T-test.

RNA isolation and RT-qPCR

The NB cell lines IMR-32 and CLB-GA were seeded and drugged as described in the 'Protein isolation' section. However, cell pellets were dissolved in QIAzol Lysis Reagent (Qiagen #79306) and snap frozen in liquid nitrogen.

RNA isolation was performed using the miRNeasy mini kit (Qiagen #217004) using the manufacturer's protocol, including the on-column DNase treatment (Qiagen #79254). Concentrations were measured using the NanoDrop (Thermo Fisher Scientific). Complementary DNA (cDNA) was made using the iScript Advanced cDNA synthesis kit (Bio-Rad #172-5038). The PCR mastermix was composed out of 5 ng cDNA, 2.5 µL SsoAdvanced Universal SYBR Green Supermix (Bio-Rad #172-5274) and 0.25 µL of forward and reverse primers (sequences can be found in Supplementary Table S6). RT-qPCR was performed using the LC-480 device (Roche). The gene expression analysis was performed using Qbase+ (CellCarta, version 3.4) and the average gene expression was scaled to the DMSO control. Graphs were made using GraphPad (version 10.3.1), error bars represent the SEM of four biological replicates and statistical analysis was performed using the multiple unpaired T-test for the single treated experiments and one-way ANOVA followed by a Dunnett's multiple comparison test for the combination treatment.

RNA sequencing

RNA was isolated as described in the 'RNA isolation and RT-qPCR' section. RNA quality was measured using the Fragment analyzer 12 capillary array prior to profiling. A total of 10 ng of RNA was used as input for the library preparation with the QuantSeq-Pool Sample-Barcoded 3' mRNA-Seq Kit (Lexogen #139.96). The manufacturer's protocol was adapted to use only half of the total volumes of the solvents, and 15 PCR cycles were used for amplification. qPCR quantification of the libraries was done using the Kapa Library Quantification Kit for the Illumina LightCycler 480 (Roche diagnostics #07960298001). RNA-seq libraries were sequenced on the Illumina NextSeq 2000 platform using the NextSeq 2000 P3 Reagents 100 Cycles paired-end kit (Illumina #20040559). Data analysis followed the workflow outlined on the Lexogen GitHub repository (https://github.com/Lexogen-Tools/quantseqpool_analysis). Briefly, sample and read quality were evaluated with FastQC (version 0.11.7). The FASTQ files were aligned to the Homo sapiens reference genome (GRCh38.96) using STAR (version 2.7.2b). Post-alignment, read counts were generated and normalized with edgeR (version 3.36.0). After performing PCA plotting, certain replicates were removed from the analysis as they did not cluster with the other replicates, indicating potential outliers or inconsistencies.

Differential expression analysis was performed using the Limma-Voom pipeline (version 3.50.3) with three or four replicates per condition. Only genes with an adjusted *P*-value < 0.05 and a logFC of ≤ -1 (down-regulated) or ≥ 1 (upregulated) were considered significant. Gene Set Enrichment Analysis (GSEA) was performed on genes ordered according to

the differential expression statistic (*t*) value. GSEA utilized gene sets from MSigDB (<https://www.gsea-msigdb.org/gsea/msigdb/>) and custom gene lists from this and previous studies (3-AP datasets: GSE161902 and ALK signaling signature [44]). After GSEA, only protein-coding genes were retained for further analysis. All figures were generated using ggplot2 (version 3.5.1), pheatmap (version 1.0.12), and pathview (version 1.42.0) packages in R.

All RNA-seq data are available through the Gene Expression Omnibus (GEO) repository (GSE279147). The gene lists can be found in Supplementary Tables S8.1–8.6.

Zebrafish housing

All procedures involving experimental animals were approved by the local animal ethics committee (Ghent University hospital, Ghent, Belgium), permit number ECD 17–100, and performed according to local guidelines and policies in compliance with national and European law.

Zebrafish were maintained in a Zebtec semi-closed recirculation housing system (Techniplast). The water had a constant temperature (27–28 °C), pH (~7.5), conductivity (~500 µS) and light/dark cycle (14 h/10 h).

Determining the maximum non-toxic tolerable dose (MNTD)

Wild type (AB) zebrafish at 3 days post fertilization were randomly distributed into groups and treated by submersion in different concentrations of TAS1553, prexasertib, SRA737 or DMSO diluted in E3 medium. Fish were exposed to treatment for 96 h and the E3 medium with compound was refreshed every 24 h. Every day, the zebrafish were screened for signs of toxicity. All zebrafish were euthanized with tricain 25x (Sigma-Aldrich #A5040-25G) after 96 h of treatment. The MNTD was defined as the highest concentration of TAS1553 and CHK1 inhibition that did not cause any signs of toxicity, including death, cardiac edema, a slower heart rate or a curved tail.

Establishment of zebrafish avatars

SK-N-AS cells were grown to 70% confluence in a T75 flask and detached from the surface using trypsin (Gibco #11580626). Next, the cells were fluorescently stained with 4 µL/mL Vybrant CM-Dil (ThermoFisher Scientific #C-7001) in PBS for 10 min at 37 °C and 10 min on ice. The cells were then washed with PBS and resuspended to a final concentration of 0.3×10^6 cells/µL in PBS. The cells were kept on ice during the injections.

Thin wall glass capillaries (World precision instruments #TW100-4) were pulled into microinjection needles using a capillary puller (Sutter instrument P-1000). Wild type (AB) zebrafish at 2 days post fertilization were anaesthetized with tricain 1x in E3 medium for 5 min and immobilized in a thin layer of low-melting-point agarose 1% (Life Technologies Europe #16520-0550) on a cover slip. Next, pulled needles and a FemtoJet® 4i microinjector (Eppendorf) were used to inject the fluorescently labelled cells into the perivitelline space of the zebrafish until a tumor with size comparable to the eye size of the zebrafish was reached. Zebrafish were removed from the agarose and sedated for 10 more minutes before they were transferred to E3 medium and incubated at 34 °C. Zebrafish xenografts were evaluated 24 h post-injection with a NikonSMZ18 stereoscope and distributed into treatment groups. Zebrafish xenografts were treated for 96 h with either DMSO, TAS1553, prexasertib, SRA737 or combination treatment by adding the compound to the E3 medium. E3 medium with compound was refreshed every 24 h. The treatment was finished 5 days post-injection and the zebrafish xenografts were euthanized with tricain 25x.

Whole mount immunofluorescent staining

Whole mount immunofluorescent staining was performed as described by M. Martinez-Lopez et al. [72]. In short, zebrafish xenografts were fixed with 4% paraformaldehyde (PFA) / 0.1% Triton X-100 at 4 °C overnight and subsequently stored in methanol at –20 °C. Zebrafish xenografts were then rehydrated by decreasing methanol concentrations, washed with PBS/0.1% Triton X-100 and bleached for 5 min with bleaching solution consisting of 30% H₂O₂ (Merck Life Science #H1009) and 10% KOH in dH₂O. Zebrafish xenografts were subsequently permeabilized by 7 min incubation in ice cold 100% acetone and blocked for 1 h at RT with blocking buffer consisting of 0.01 g/mL BSA, 1% DMSO, 0.5% Triton X-100 and 0.015% goat serum diluted in 1x PBS. Next, xenografts were incubated 1 h at RT and overnight at 4 °C with primary antibody rabbit anti-cleaved caspase-3. The samples were washed the next day with PBS/0.1% Triton X-100 and PBS/0.05% Tween and incubated 1 h at RT and overnight at 4 °C

with secondary antibody and 1% Hoechst in blocking buffer. Afterwards, the zebrafish xenografts were washed with PBS/0.05% Tween-20, fixed with 4% PFA/0.1% Triton X-100 for 20 min and mounted between two coverslips with Mowiol (Sigma-Aldrich 81381-50 G). Images were taken with a Zeiss Spinning Disk confocal microscope with 10x water objective and 5 μm z-stack interval.

Cleaved caspase-3 quantification

Images were analyzed using Fiji/ImageJ (version 1.53c). First, the tumor volume for each xenograft tumor was obtained by defining and measuring the tumor area of each Z-stack, multiplying it with the 5 μm Z-stack interval and adding up these Z-stack volumes. Next, the total number of cleaved caspase-3 positive cells was counted for each tumor using the Cell Counter plug-in of Fiji/ImageJ and this count was subsequently divided by the tumor volume to obtain the number of cleaved caspase-3 positive cells per mm^3 tumor.

DATA AVAILABILITY

The RNA sequencing data obtained during this study are available through GEO repository with the accession number GSE279147 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279147>).

REFERENCES

- Zeman MK, Cimprich KA. Causes and consequences of replication stress. *Nat Cell Biol.* 2014;16:2–9.
- Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. *Proc Natl Acad Sci USA.* 2011;108:3336–41.
- Durinck K, Irwin MS. DNA repair and replicative stress addiction in neuroblastoma. *EJC Paediatr Oncol.* 2024;4:100177.
- Blosser WD, Dempsey JA, McNulty AM, Rao X, Ebert PJ, Lowery CD, et al. A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib. *Oncotarget.* 2020;11:216–36.
- Szydzik J, Lind DE, Arefin B, Kurhe Y, Umapathy G, Siaw JT, et al. ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. *Nat Commun.* 2021;12:6813.
- Borenäs M, Umapathy G, Lind DE, Lai WY, Guan J, Johansson J, et al. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition. *Proc Natl Acad Sci USA.* 2024;121:e2315242121.
- Nunes C, Depestel L, Mus L, Keller KM, Delhaye L, Louwagie A, et al. RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. *Sci Adv.* 2022;8:eabn1382.
- Aye Y, Li M, Long MJC, Weiss RS. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. *Oncogene.* 2014;34:2011–21.
- Chabes A, Thelander L. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. *J Biol Chem.* 2000;275:17747–53.
- D'Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. *Cell.* 2012;149:1023–34.
- Bokhari AA, Lai WY, Le AT, Gabre JL, Chuang TP, Fransson S, et al. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. *Lung Cancer.* 2022;171:103–14.
- Jin CY, Du L, Nuerlan AH, Wang XL, Yang YW, Guo R. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. *Aging (Albany NY).* 2020;13:3518–35.
- Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, et al. A novel mechanism driving poor-prognosis prostate cancer: Overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2). *Clin Cancer Res.* 2019;25:4480–92.
- Granieri L, Marocchi F, Melixetian M, Mohammadi N, Nicoli P, Cuomo A, et al. Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. *Cell Rep.* 2022;40:111396.
- Fatkhutdinov N, Sproesser K, Krepler C, Liu Q, Brafford PA, Herlyn M, et al. Targeting RRM2 and mutant BRAF is a novel combinatorial strategy for melanoma. *Mol Cancer Res.* 2016;14:767–75.
- Koppenhafer SL, Goss KL, Terry WW, Gordon DJ. Inhibition of the ATR-CHK1 pathway in Ewing sarcoma cells causes DNA damage and apoptosis via the CDK2-mediated degradation of RRM2. *Mol Cancer Res.* 2020;18:91–104.
- Ohmura S, Marchetto A, Orth MF, Li J, Jabar S, Ranft A, et al. Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. *Mol Cancer.* 2021;20:97.
- Yang M, Yao P, Lang X, Li X, Zhang D. Ribonucleotide reductase subunit M2 promotes proliferation and epithelial-mesenchymal transition via the JAK2/STAT3 signaling pathway in retinoblastoma. *Bioengineered.* 2021;12:12800–11.
- Giang LH, Wu KS, Lee WC, Chu SS, Do AD, Huang MH, et al. RRM2 inhibition alters cell cycle through ATM/Rb/E2F1 pathway in atypical teratoid rhabdoid tumor. *Neoplasia.* 2024;58:101075.
- Giang LH, Wu KS, Lee WC, Chu SS, Do AD, Changou CA, et al. Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor. *J Exp Clin Cancer Res.* 2023;42:346.
- Brown A, Pan Q, Fan L, Indersie E, Tian C, Timchenko N, et al. Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse. *Commun Biol.* 2023;6:249.
- Atkin CL, Thelander L, Reichard P, Lang G. Iron and Free Radical in Ribonucleotide Reductase: EXCHANGE OF IRON AND MÖSSBAUER SPECTROSCOPY OF THE PROTEIN B2 SUBUNIT OF THE ESCHERICHIA COLI ENZYME. *J Biol Chem.* 1973;248:7464–72.
- Lassmann G, Thelander L, Gräslund A. EPR stopped-flow studies of the reaction of the tyrosyl radical of protein r2 from ribonucleotide reductase with hydroxyurea. *Biochem Biophys Res Commun.* 1992;188:879–87.
- Shao J, Zhou B, Di Bilio AJ, Zhu L, Wang T, Qi C, et al. A Ferrous-triapipe complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. *Mol Cancer Ther.* 2006;5:586–92.
- Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA. Phase II study of Triapipe in patients with metastatic renal cell carcinoma: A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). *Invest N Drugs.* 2007;25:471–7.
- Zhan Y, Jiang L, Jin X, Ying S, Wu Z, Wang L, et al. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. *Biomedicine Pharmacother.* 2021;133:110996.
- Scott DE, Francis-Newton NJ, Marsh ME, Coyne AG, Fischer G, Moschetti T, et al. A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death. *Cell Chem Biol.* 2021;28:835–47.
- Zhang X, Chen X, Lu L, Fang Q, Liu C, Lin Z. Identification of small-molecule inhibitors of human MUS81-EME1/2 by FRET-based high-throughput screening. *Bioorg Med Chem.* 2023;90:117383.
- Ueno H, Hoshino T, Yano W, Tsukioka S, Suzuki T, Hara S, et al. TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress. *Commun Biol.* 2022;5:571.
- Corrales-Guerrero S, Cui T, Castro-Aceituno V, Yang L, Nair S, Feng H, et al. Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1. *Cancer Lett.* 2023;570:216308.
- Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. *Nat Rev Cancer.* 2023;23:275–94.
- Ozgencl M, Dullovi A, Higos RCC, Hořejší Z, Bellelli R. The linker histone H1–BRCA1 axis is a crucial mediator of replication fork stability. *Life Sci Alliance.* 2023;6:e202301933.
- Tan JL, Fogley RD, Flynn RA, Ablain J, Yang S, Saint-André V, et al. Stress from nucleotide depletion activates the transcriptional regulator HEXIM1 to suppress melanoma. *Mol Cell.* 2016;62:34–46.
- Ma J, Ren D, Wang Z, Li W, Li L, Liu T, et al. CK2-dependent degradation of CBX3 dictates replication fork stalling and PARP inhibitor sensitivity. *Sci Adv.* 2024;10:eadk8908.
- De Wyn, Zimmerman J, Weichert MW, leahey N, Nunes C, Cheung BB, et al. MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH-MYCN-driven neuroblastoma formation. *Cancers (Basel).* 2021;13:4783.
- Regan PL, Jacobs J, Wang G, Torres J, Edo R, Friedmann J, et al. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. *Int J Oncol.* 2011;38:105–12.
- Lamers F, Van Der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, et al. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. *Endocr Relat Cancer.* 2011;18:657–68.
- Goss KL, Koppenhafer SL, Waters T, Terry WW, Wen KK, Wu M, et al. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. *Oncogene.* 2021;40:564–77.
- Lawrence JM, Tan SH, Kim DC, Tan KE, Schroeder SE, Yeo KS, et al. Diverse engraftment capability of neuroblastoma cell lines in zebrafish larvae. *Zebrafish.* 2024;21:385–93.
- King C, Diaz HB, McNeely S, Barnard D, Dempsey J, Blosser W, et al. LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms. *Mol Cancer Ther.* 2015;14:2004–13.
- Osborne JD, Matthews TP, McHardy T, Proisy N, Cheung KMJ, Lainchbury M, et al. Multiparameter lead optimization to give an oral Checkpoint Kinase 1 (CHK1) inhibitor clinical candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). *J Med Chem.* 2016;59:5221–37.

42. Yao Y, Zhang Q, Li Z, Zhang H. MDM2: current research status and prospects of tumor treatment. *Cancer Cell Int.* 2024;24:170.
43. Valentijn LJ, Koster J, Haneveld F, Aissa RA, Van Sluis P, Broekmans MEC, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. *Proc Natl Acad Sci USA.* 2012;109:19190–5.
44. Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, et al. Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma: Implications for targeted treatment. *Clin Cancer Res.* 2015;21:3327–39.
45. Van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. *Nat Genet.* 2017;49:1261–6.
46. Wilkinson ME, Charenton C, Nagai K. RNA splicing by the spliceosome. *Annu Rev Biochem.* 2020;89:359–88.
47. Nguyen THD, Galej WP, Bai XC, Savva CG, Newman AJ, Scheres SHW, et al. The architecture of the spliceosomal U4/U6.U5 tri-snRNP. *Nature.* 2015;523:47–52.
48. Shkreta L, Chabot B. The RNA splicing response to DNA damage. *Biomolecules.* 2015;5:2935–77.
49. Paulsen RD, Soni DV, Wollman R, Hahn AT, Yee MC, Guan A, et al. A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. *Mol Cell.* 2009;35:228–39.
50. Fishbein WN, Carbone PP, Freireich EJ, Misra D, Frei E. Clinical trials of hydroxyurea in patients with cancer and leukemia. *Clin Pharm Ther.* 1964;5:574–80.
51. Hankins JS, Aygun B, Nottage K, Thornburg C, Smeltzer MP, Ware RE, et al. From infancy to adolescence: Fifteen years of continuous treatment With hydroxyurea in sickle cell anemia. *Med (Baltim).* 2014;93:e215.
52. Yen Y, Grill SP, Dutschman GE, Chang CN, Zhou BS, Cheng YC. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. *Cancer Res.* 1994;54:3686–91.
53. Zhou B, Sen, Tsai P, Ker R, Tsai J, Ho R, Yu J, et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. *Clin Exp Metastasis.* 1998;16:43–9.
54. Finch RA, Liu MC, Grill SP, Rose WC, Loomis R, Vasquez KM, et al. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. *Biochem Pharm.* 2000;59:983–91.
55. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. *Cancer Res.* 1991;51:6110–7.
56. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. *Mol Pharm.* 1990;38:567–72.
57. Xu H, Faber C, Uchiki T, Racca J, Dealwis C. Structures of eukaryotic ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly. *Proc Natl Acad Sci USA.* 2006;103:4028–33.
58. Engström Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. *J Biol Chem.* 1985;260:9114–6.
59. Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. *Oncotarget.* 2017;8:38022–43.
60. Ditano JP, Eastman A. Comparative activity and off-target effects in cells of the CHK1 inhibitors MK-8776, SRA737, and LY2606368. *ACS Pharm Transl Sci.* 2021;4:730–43.
61. Schoonen PM, Kok YP, Wierenga E, Bakker B, Fojier F, Spierings DCJ, et al. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells. *Mol Oncol.* 2019;13:2422–40.
62. Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. *J Clin Invest.* 2019;129:1211–28.
63. Taniguchi H, Chakraborty S, Takahashi N, Banerjee A, Caesar R, Zhan YA, et al. ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. *Sci Adv.* 2024;10:eado4618.
64. Blavier L, Yang RM, Declerck YA. The tumor microenvironment in neuroblastoma: New players, new mechanisms of interaction and new perspectives. *Cancers (Basel).* 2020;12:2912.
65. Tanikawa M, Sanjiv K, Helleday T, Herr P, Mortusewicz O. The spliceosome U2 snRNP factors promote genome stability through distinct mechanisms; transcription of repair factors and R-loop processing. *Oncogenesis.* 2016;5:e280.
66. Nguyen HD, Leong WY, Li W, Reddy PNG, Sullivan JD, Walter MJ, et al. Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndrome. *Cancer Res.* 2018;78:5363–74.
67. Zhou Z, Gong Q, Wang Y, Li M, Wang L, Ding H, et al. The biological function and clinical significance of SF3B1 mutations in cancer. *Biomark Res.* 2020;8:38.
68. Langenberg KPS, van Hooff SR, Koopmans B, Strijker JGM, Kholosy WM, Ober K, et al. Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine. *Eur J Cancer.* 2025;218:115275.
69. Nunes C, Anckaert J, De Vloed F, De Wyn J, Durinck K, Vandesompele J, et al. HTSplotter: An end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening. *PLoS One.* 2024;19:e0296322.
70. lanevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. *Nucleic Acids Res.* 2022;50:W739–43.
71. Nguyen U, Squaglia N, Boge A, Fung PA. The Simple Western™: a gel-free, blot-free, hands-free Western blotting reinvention. *Nat Methods.* 2011;8:v–vi.
72. Martinez-Lopez M, Póvoa V, Fior R. Generation of zebrafish larval xenografts and tumor behavior analysis. *J visualized Exp.* 2021;172:e62373.

ACKNOWLEDGEMENTS

We would like to thank dr. Igor Fijalkowski and prof. dr. Panagiotis Ntziachristos for the guidance and support with their expertise in RNA splicing. We thank the Zebrafish Core Facility (zfg@UGent.be) for support and care taking of the zebrafish. We thank the PDXcore for maintaining the PDX models (<https://pdxghentcore.ugent.be>). This work was supported by Villa Joep (STI-DIV.2020.0019.01); Kom op Tegen Kanker (KOTK) (STI.VLK.2022.0003.01); Hubert Gouin (INT.DIV.2023.0031.01); Kinderkanker Fonds (KKF) (STI.DIV.2023.0013.01); Stichting Tegen Kanker (STK) (STI.STK.2023.0017.01), and Olivia Fund. The laboratory of T.G.P.G. acknowledges funding of the Barbara and Wilfried Mohr foundation as well as of the European Union (ERC, CANCER-HARAKIRI, 101122595). Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or the European Research Council. The laboratory of T.G.P.G. would like to thank Taiho Pharmaceutical for the generous provision of TAS1553 to perform their in vitro experiments.

AUTHOR CONTRIBUTIONS

The study was conceptualized by I.H.N., S.L., S.O., T.G.P.G., L.M.M., T.L., N.V.R., B.D.W., F.S., A.V.H., L.D., K.D.; Experiments were performed by I.H.N., S.L., F.D.V., F.M., E.S., A.P.E.R., A.J.; Results were analyzed by I.H.N., S.L., S.B., S.O., L.D.; The paper was written by I.H.N., S.L., S.B., S.O.; All authors reviewed the manuscript and provided feedback; Funding was obtained by T.G.P.G., T.L., F.S., K.D.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41419-026-08514-6>.

Correspondence and requests for materials should be addressed to Kaat Durinck.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026